NCT05250856 - CNP-201 in Subjects With Peanut Allergy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 14, 2022

Primary Completion Date

December 12, 2023

Study Completion Date

December 12, 2023

Conditions

Peanut Allergy

Interventions

DRUG

CNP-201

CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~5 μg of PPE per mg of PLGA.

DRUG

Placebo

Placebo, (0.9% Sodium Chloride for IV infusion)

Trial Locations (17)

20815

Institute for Asthma & Allergy, Chevy Chase

23226

Clinical Research Partners, Richmond

29420

National Allergy and Asthma Research, LLC, North Charleston

35209

AllerVie Clinical Research, Birmingham

43213

Aventiv Research, Inc, Columbus

60062

Allergy & Asthma Medicaal Group and Research Center, San Diego

60612

Rush University Medical Center, Chicago

61761

Sneeze, Wheeze and Itch Associates, LLC, Normal

66210

Meridian Clinical Research. LLC, Overland Park

74136

Vital Prospects Clinica Research Institute, Tulsa

75230

Allergy Partners of North Texas Research, Dallas

75231

Pharmaceutical Research & Consulting, Inc, Dallas

77598

Tranquil Clinical and Research Consulting Services, Houston

79903

Western Sky Medical Research, El Paso

90806

Long Beach Clinical Trials, LLC, Long Beach

92691

Southern California Research, Mission Viejo

98115

Seattle Allergy & Asthma Research Institute, Seattle